磷酸盐尿性间叶肿瘤:单中心十例患者的治疗与结局
回顾性纳入10例经组织学诊断的磷酸盐尿性间叶肿瘤患者,中位肿瘤大小1.9 cm,中位诊断延迟3年,术前FGF-23均升高。6例手术切除、3例经皮消融、1例拒绝治疗;仅1例局部复发,无转移,末次随访9例无病生存。作者认为能实现阴性切缘且无明显并发症时手术是标准治疗,手术难以到达区域的小肿瘤可成功行射频消融或冷冻消融。
要点
- 磷酸盐尿性间叶肿瘤罕见,表现为肿瘤诱导性骨软化症,症状非特异,中位诊断延迟3年。
- 术前FGF-23在所有病例均升高(中位423.5 RU/mL),除1例外均有低磷血症(中位1.9 mg/dL)。
- 手术切除是能实现阴性切缘且无明显并发症时的标准治疗;手术难以到达区域的小肿瘤可行射频消融或冷冻消融。
核心结论
- 磷酸盐尿性间叶肿瘤罕见且症状非特异;能实现阴性切缘且无明显并发症时手术是标准治疗,手术难以到达区域的小肿瘤可成功行射频消融或冷冻消融。
研究设计与样本
- 单中心回顾性研究,经组织学诊断的位于中轴或附肢骨骼或周围软组织的磷酸盐尿性间叶肿瘤患者共10例。
关键影像表现/征象
- 中位肿瘤大小1.9 cm(范围1.1至6.1)。
- 中位症状出现至诊断时间3年(范围0.5至15年)。
- 除1例外所有患者均有低磷血症(中位1.9 mg/dL,范围1.2至3.2)。
- 术前FGF-23在所有病例均升高(中位423.5 RU/mL,范围235至8950)。
临床应用与阅片要点
- 6例接受手术切除,3例接受经皮治疗(射频消融或冷冻消融),1例拒绝治疗。
- 仅1例出现局部复发,无患者出现转移。
- 末次随访时9例无疾病证据,1例带病生存。
- 作者认为能实现阴性切缘且无明显并发症时手术是标准治疗,手术难以到达区域的小肿瘤可成功行射频消融或冷冻消融。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Phosphaturic mesenchymal tumor (PMT) is a rare tumor that causes tumor-induced osteomalacia. Patients present with non-specific symptoms secondary to renal phosphate wasting and decreased bone mineralization. We sought to assess: (1) What are the common presenting features, laboratory and imaging findings, histologic findings of phosphaturic mesenchymal tumors? (2) What are the available treatment strategies for phosphaturic mesenchymal tumors and their long-term outcomes in terms of local recurrence and symptom control after treatment?
METHODS: We retrospectively identified patients with a histologic diagnosis of PMT located in the axial or appendicular skeleton, or surrounding soft tissues. A total of 10 patients were finally included in our study.
RESULTS: Median tumor size was 1.9 cm (range, 1.1 to 6.1) and median time from symptom onset to diagnosis was 3 years (range, 0.5 to 15 years). All patients but one presented with hypophosphatemia (median 1.9 mg/dL, range 1.2 to 3.2). Pre-operative FGF-23 was elevated in all cases (median 423.5 RU/mL, range 235 to 8950). Six patients underwent surgical resection, three were treated percutaneously (radiofrequency ablation or cryoablation), and one refused treatment. Only one patient developed local recurrence and no patients developed metastatic disease. At last follow-up, nine patients showed no evidence of disease and one was alive with disease.
CONCLUSION: Phosphaturic mesenchymal tumor is a rare tumor presenting with non-specific symptoms. Surgery is the standard treatment when negative margins can be achieved without significant morbidity. In patients with small tumors in surgically-inaccessible areas, radiofrequency ablation or cryoablation can be performed successfully.
引用
- Gonzalez MR, Patel N, Connolly JJ, et al. Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution. Skeletal Radiol. 2024. PMID: 38351410. doi:10.1007/s00256-024-04614-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。